Aqua Medical Advances with Series B Funding
Aqua Medical, a company based in Pleasanton, California, has announced the successful closing of its Series B funding round on September 23, 2026. The funding was led by Relevance Ventures, although the exact amount raised remains undisclosed. Aqua Medical is known for its innovative outpatient treatment aimed at improving control for individuals with type 2 diabetes through a 30-minute procedure conducted via endoscopy.
Leadership and Vision
The company is headed by Bob Haggerty, who serves as CEO and President, alongside Lloyd Mencinger, who also holds the titles of President and CEO. These leaders guide Aqua Medical's mission to enhance diabetes management through its unique medical interventions.
Use of Funds
While specific plans for the newly acquired funds have not been disclosed, it is anticipated that the capital will be used to further develop Aqua Medical's technology, expand its market reach, and potentially enhance its operational capabilities.
Strategic Importance
The investment by Relevance Ventures underscores the confidence in Aqua Medical's approach to diabetes care. By focusing on a minimally invasive treatment option, the company aims to provide a more controlled and efficient solution for managing type 2 diabetes.
As Aqua Medical continues to grow, it remains committed to advancing its medical solutions to meet the needs of patients and healthcare providers alike.